Application of lactobacillus reuteri in preparation of medicine for treating acute hepatic failure (AHF)

A technology of Lactobacillus reuteri and acute liver failure, which is applied in the field of application of Lactobacillus reuteri in the preparation of drugs for the treatment of acute liver failure. Liver inflammation and other problems

Inactive Publication Date: 2021-01-05
ZHEJIANG UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is not yet clear whether prophylactic supplementation of Lactobacillus reuteri can improve the impaired intestinal barrier and liver inflammation in patients with liver failure, and in what way; in addition, in addition to artificial liver and symptomatic treatment, there is still a lack of comprehensive treatment for acute liver failure. microecological adjuvant therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lactobacillus reuteri in preparation of medicine for treating acute hepatic failure (AHF)
  • Application of lactobacillus reuteri in preparation of medicine for treating acute hepatic failure (AHF)
  • Application of lactobacillus reuteri in preparation of medicine for treating acute hepatic failure (AHF)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0029] 1. Experimental grouping and treatment:

[0030] Grouping of rats: divided into 3 groups, respectively, Lactobacillus reuteri supplementation group (that is, Lactobacillus reuteri, and galactosamine model), positive control group (that is, the same amount of PBS, and galactose amine modeling), blank control group (no probiotics, no galactosamine modeling).

[0031] Lactobacillus reuteri gavage: Dissolve Lactobacillus reuteri in sterile PBS solution, and give 1*10E9 CFU / ml / cause / day. The model group was administered by gavage continuously for 14 days. At the same time, the control group was given PBS solution for 14 days.

[0032] Induction of liver failure: After fasting for 12 hours, intraperitoneal injection of 1.1 g / kg body weight of galactosamine was given to the control group and the model group respectively to induce liver failure.

[0033] 2. Improvement effect of Lactobacillus reuteri on liver inflammation in rats with galactosamine-induced acute liver failur...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of lactobacillus reuteri in preparation of a medicine for treating acute liver failure (AHF). In-depth research aiming at relieving liver and intestinal inflammation is conducted, and research objects are divided into a blank control group, a positive control group and a supplementary lactobacillus reuteri group. The result finds that the liver transaminase level, inflammatory factor IL-17 and intrahepatic inflammatory cell in the supplementary lactobacillus reuteri group are decreased, that is, the lactobacillus reuteri is supplemented every day preventively, so that liver and intestinal inflammation can be relieved when AHF occurs. In the context, it is desirable to alleviate liver and intestinal inflammation supplementing Lactobacillus reuteri preventively in healthy populations.

Description

technical field [0001] The invention relates to the use of Lactobacillus reuteri in preparing medicine for treating acute liver failure. Background technique [0002] Acute hepatic failure (acute hepatic failure. AHF) refers to a group of severe clinical syndromes in which a large number of hepatic cell necrosis and severe liver function damage occur in a short period of time without basic liver disease, and hepatic encephalopathy is caused. Its clinical features are no history of chronic liver disease in the past, sudden onset, rapid onset of jaundice, liver failure, hemorrhage, and neuropsychiatric symptoms. Multiple organ dysfunction syndrome can be combined in a short period of time. The fatality rate of this disease is high, and it belongs to one of the critical illnesses. At present, there is no specific treatment method. [0003] Current treatments include: [0004] 1. Etiological treatment [0005] Antiviral therapy can be used for acute liver failure caused by v...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/747A61P1/16A61P1/00A61P29/00
CPCA61K35/747A61P1/16A61P1/00A61P29/00
Inventor 陈智周琦惠朱海红连雯雯
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap